After finishing at $90.80 in the prior trading day, Blueprint Medicines Corp (NASDAQ: BPMC) closed at $89.67, down -1.24%. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 600539 shares were traded.
Ratios:
Our goal is to gain a better understanding of BPMC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 5.93 whereas as Long-Term Debt/Eq ratio is at 5.30.
On August 21, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $65 to $66.
Wells Fargo Upgraded its Equal Weight to Overweight on July 31, 2023, whereas the target price for the stock was revised from $55 to $82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 when Murray Christopher K. sold 5,000 shares for $100.00 per share. The transaction valued at 500,000 led to the insider holds 24,495 shares of the business.
Albers Jeffrey W. sold 25,000 shares of BPMC for $2,047,800 on Jan 25. The Director now owns 176,050 shares after completing the transaction at $81.91 per share. On Dec 22, another insider, Hurley Ariel, who serves as the PRINCIPAL ACCOUNTING OFFICER of the company, sold 714 shares for $90.00 each. As a result, the insider received 64,260 and left with 14,324 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5.49B and an Enterprise Value of 5.11B. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.02 while its Price-to-Book (P/B) ratio in mrq is 41.98. Its current Enterprise Value per Revenue stands at 20.50 whereas that against EBITDA is -10.87.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $101.00, while it has fallen to a 52-week low of $40.48. The 50-Day Moving Average of the stock is 84.75, while the 200-Day Moving Average is calculated to be 64.49.
Shares Statistics:
The stock has traded on average 886.92K shares per day over the past 3-months and 1.11M shares per day over the last 10 days, according to various share statistics. A total of 61.15M shares are outstanding, with a floating share count of 60.07M. Insiders hold about 1.90% of the company’s shares, while institutions hold 104.98% stake in the company. Shares short for BPMC as of Feb 15, 2024 were 4.63M with a Short Ratio of 5.22, compared to 4.37M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.56% and a Short% of Float of 10.16%.
Earnings Estimates
Its stock is currently analyzed by 15 different market analysts. On average, analysts expect EPS of -$1.67 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.8, while EPS last year was -$2.15. The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.22 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.37 and -$6.28 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$2.78, with 15 analysts recommending between -$0.27 and -$6.46.
Revenue Estimates
14 analysts predict $80.34M in revenue for the current quarter. It ranges from a high estimate of $86.7M to a low estimate of $72M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $63.29M, an estimated increase of 26.90% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $91.95M, an increase of 102.20% over than the figure of $26.90% in the same quarter last year. There is a high estimate of $101.9M for the next quarter, whereas the lowest estimate is $87M.
A total of 16 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $449M, while the lowest revenue estimate was $372M, resulting in an average revenue estimate of $392.72M. In the same quarter a year ago, actual revenue was $249.38M, up 57.50% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $596.03M in the next fiscal year. The high estimate is $738.9M and the low estimate is $481.18M. The average revenue growth estimate for next year is up 51.80% from the average revenue estimate for this year.
